Last update 08 May 2025
Eisai China, Inc.

Eisai China, Inc.

Subsidiary Company|1996|Jiangsu Sheng, China|
www.eisai.com.cn

Overview

Tags

Other Diseases
Endocrinology and Metabolic Disease
Congenital Disorders
Small molecule drug
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease3
Nervous System Diseases2
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug3
Chemical drugs1
Top 5 TargetCount
ACHE(Acetylcholinesterase)1
5-HT1A receptor x 5-HT1B receptor x 5-HT1D receptor1
DNMT1(DNA (cytosine-5)-methyltransferase 1)1
URAT1(Uric acid transporter 1)1

Related

5
Drugs associated with Eisai China, Inc.
Dotinurad
Target
URAT1
Mechanism
URAT1 inhibitors
Active Org.
Eisai Co., Ltd.Eisai Co., Ltd. [+3]
Originator Org.
Fuji Yakuhin Co., Ltd.Fuji Yakuhin Co., Ltd.
Active Indication
Gout [+1]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Japan
First Approval Date23 Jan 2020
Cinitapride Tartrate
Target
5-HT1A receptor x 5-HT1B receptor x 5-HT1D receptor
Mechanism
5-HT1A receptor agonists [+2]
Active Org.
Eisai China, Inc.Eisai China, Inc. [+1]
Originator Org.
Almirall SAAlmirall SA
Active Indication
Dyspepsia [+1]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Spain
First Approval Date16 Apr 2010
Donepezil Hydrochloride
Target
ACHE
Mechanism
AChE inhibitors
Active Org.
Aulbio Co., Ltd.Aulbio Co., Ltd.
 [+13]
Originator Org.
Eisai Co., Ltd.Eisai Co., Ltd.
Active Indication
Dementia [+3]
Inactive Indication
Advanced cancer [+13]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date25 Nov 1996
17
Clinical Trials associated with Eisai China, Inc.
CTR20250484
/ RecruitingPhase 1/2
E7386与其他抗癌药物（E7080/甲磺酸仑伐替尼胶囊）联合治疗实体瘤受试者的开放研究
[Translation] An open-label study of E7386 in combination with other anticancer drugs (E7080/lenvatinib mesylate capsules) in subjects with solid tumors
CTR20220562
/ CompletedPhase 1
一项在中国健康受试者中进行的Dotinurad单次和多次给药的药代动力学研究
[Translation] A single and multiple-dose pharmacokinetic study of Dotinurad in healthy Chinese subjects
CTR20212197
/ CompletedPhase 3
一项Dotinurad（4 mg）对比非布司他（40 mg）治疗痛风受试者的随机、多中心、双盲研究
[Translation] A randomized, multicenter, double-blind study of dotinurad (4 mg) versus febuxostat (40 mg) in subjects with gout
100 Clinical Results associated with Eisai China, Inc.
Login to view more data
0 Patents (Medical) associated with Eisai China, Inc.
Login to view more data
100 Deals associated with Eisai China, Inc.
Login to view more data
100 Translational Medicine associated with Eisai China, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
4
1
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free